CN-121987619-A - Use of isopsoralen in preventing and/or treating colorectal cancer

Abstract

The application relates to the technical field of cancer treatment, in particular to application of isopsoralen or pharmaceutically acceptable salt, solvate or metabolite thereof in preventing and/or treating colorectal cancer. Experiments prove that the isopsoralen can effectively reduce the number of tumors, inhibit the generation of inflammatory factors and inhibit the occurrence of cancers, and has good safety.

Inventors

• YANG WEIPENG
• LIU JIANYAO
• LIU HAIFAN
• ZHANG CAIJUAN
• FENG XUE
• WANG DUNFANG
• LIU BIN
• ZHU LIN
• SUN QIYUE

Assignees

• 中国中医科学院中药研究所

Dates

Publication Date

20260508

Application Date

20260115

Claims (10)

1. 1. Use of isopsoralen or a pharmaceutically acceptable salt, solvate or metabolite thereof in the manufacture of a medicament for the prevention and/or treatment of colorectal cancer.
2. 2. The use of isopsoralen or a pharmaceutically acceptable salt, solvate or metabolite thereof as sole active ingredient in the manufacture of a medicament for the prevention and/or treatment of colorectal cancer.
3. 3. Use of isopsoralen or a pharmaceutically acceptable salt, solvate or metabolite thereof in the manufacture of a medicament for the adjuvant prevention and/or treatment of colorectal cancer.
4. 4. The use according to any one of claims 1-3, wherein said medicament comprises isopsoralen or a pharmaceutically acceptable salt, solvate or metabolite thereof and a pharmaceutically acceptable adjuvant.
5. 5. The use according to claim 4, wherein the pharmaceutically acceptable excipients comprise one or more of diluents, wetting agents, fillers, binders, lubricants, disintegrants, antioxidants, buffers, suspending agents, solubilizers, thickeners, stabilizers, flavoring agents or preservatives.
6. 6. The use according to any one of claims 1 to 5, wherein the medicament is in the form of a tablet, pill, powder, granule, capsule, lozenge, syrup, emulsion, microemulsion, suspension, injection, spray, lotion, ointment, plaster, paste, drop pill or gel.
7. 7. The use according to any one of claims 1-6, wherein said preventing and/or treating colorectal cancer comprises administering to a subject in need thereof a prophylactically and/or therapeutically effective amount of isopsoralen or a pharmaceutically acceptable salt, solvate or metabolite thereof or said medicament.
8. 8. The use according to claim 7, wherein said administration comprises gastrointestinal or parenteral administration.
9. 9. The use according to claim 8, wherein the single administration dose is 0.01-1000mg isopsoralen or a pharmaceutically acceptable salt, solvate or metabolite thereof/kg body weight.
10. 10. The use according to claim 7 or 8, wherein the frequency of administration is 1 time per day, 2 times per day, 3 times per day, 1 time per day 2 days, 1 time per day 3 or 1 time per day 4.

Description

Use of isopsoralen in preventing and/or treating colorectal cancer Technical Field The application relates to the technical field of cancer treatment, in particular to application of isopsoralen or pharmaceutically acceptable salt, solvate or metabolite thereof in preventing and/or treating colorectal cancer. Background Colorectal cancer (colorectal cancer, CRC) is one of the most common malignancies, with high incidence. Currently, the main measure in treating colorectal cancer is endoscopic resection, which effectively reduces cancer mortality. But has higher invasive performance of excision under the lens and higher recurrence rate, and is easy to bring pain to patients. The study reports that aspirin, folic acid, celecoxib, calcium agent, vitamin D, metformin and the like have the effect of preventing recurrence and deterioration of intestinal adenoma, but the curative effect and the drug safety lack of large-sample clinical data support. To date, clinically specific therapeutic agents for this disease remain blank. Therefore, there is a need to discover drugs that are safe and effective in preventing and controlling colorectal cancer. Disclosure of Invention In a first aspect, the application provides the use of isopsoralen or a pharmaceutically acceptable salt, solvate or metabolite thereof for the manufacture of a medicament for the prevention and/or treatment of colorectal cancer. In a second aspect, the present application provides the use of isopsoralen or a pharmaceutically acceptable salt, solvate or metabolite thereof as sole active ingredient in the manufacture of a medicament for the prevention and/or treatment of colorectal cancer. In a third aspect of the present application, there is provided the use of isopsoralen or a pharmaceutically acceptable salt, solvate or metabolite thereof in the manufacture of a medicament for the auxiliary prevention and/or treatment of colorectal cancer. In a fourth aspect of the present invention, there is provided a medicament for preventing and/or treating colorectal cancer, the medicament comprising isopsoralen or a pharmaceutically acceptable salt, solvate or metabolite thereof. The isopsoralen or a pharmaceutically acceptable salt, solvate or metabolite thereof is effective to ameliorate the reduction in colon length caused by colorectal cancer. The isopsoralen or pharmaceutically acceptable salts, solvates or metabolites thereof increase the expression level of PCNA protein associated with active proliferation of cells in colon tissue. The isopsoralen or pharmaceutically acceptable salt, solvate or metabolite thereof is effective in reducing tumor number and inhibiting the occurrence of cancer. The isopsoralen or a pharmaceutically acceptable salt, solvate or metabolite thereof is effective in protecting the intestinal barrier (e.g., up-regulating the expression levels of the zonulin ZO-1, occludin and mucin MUC 2), significantly improving the colonic tissue morphology. The isopsoralen or a pharmaceutically acceptable salt, solvate, or metabolite thereof is effective to inhibit the production of inflammatory factors such as IL-1β, IL 6, TNF- α. The colorectal cancer (colorectal cancer, CRC) is a colitis-associated cancer (colitis-associated cancer, CAC). The medicine comprises isopsoralen or pharmaceutically acceptable salt, solvate or metabolite thereof, and pharmaceutically acceptable auxiliary materials. The medicament may contain 0.01-99.5% (e.g., 0.01%, 0.1%, 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.5%) by weight of the isopsoralen or a pharmaceutically acceptable salt, solvate or metabolite thereof. Preferably, the pharmaceutically acceptable auxiliary materials comprise one or more than two of diluents, wetting agents, fillers, binders, lubricants, disintegrants, antioxidants, buffers, suspending agents, solubilizers, thickeners, stabilizers, flavoring agents or preservatives. The medicine is in the form of tablet, pill, powder, granule, capsule, lozenge, syrup, emulsion, microemulsion, suspension, injection, spray, lotion, ointment, plaster, paste, dripping pill or gel. Preferably an injection. The preventing and/or treating colorectal cancer comprises administering to a subject in need thereof a prophylactically and/or therapeutically effective amount of isopsoralen or a pharmaceutically acceptable salt, solvate or metabolite thereof or the medicament. The administration includes gastrointestinal or parenteral administration. Such as oral, intravenous, intramuscular, subcutaneous, intradermal, organoleptic, intranasal, intraocular, instillation, intracerebral, intrathecal, transdermal, intrarectal, and the like. The single dose is 0.01-1000mg isopsoralen or a pharmaceutically acceptable salt, solvate or metabolite thereof per kg body weight, e.g. 0.01, 0.1, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 100, 1000, preferably 1-5 isopsoralen or a pharmaceutic